These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 20859223)

  • 1. Abatacept therapy for rheumatoid arthritis in the setting of hepatitis C infection.
    Mahajan TD; Hooker R; Maher L; Brown G; Reimold A
    J Clin Rheumatol; 2010 Oct; 16(7):332-4. PubMed ID: 20859223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T-cell agents in the treatment of rheumatoid arthritis.
    Solomon GE
    Bull NYU Hosp Jt Dis; 2010; 68(3):162-5. PubMed ID: 20969545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abatacept in the treatment of rheumatoid arthritis.
    Todd DJ; Costenbader KH; Weinblatt ME
    Int J Clin Pract; 2007 Mar; 61(3):494-500. PubMed ID: 17313619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abatacept as add-on therapy for rheumatoid arthritis.
    Allison C
    Issues Emerg Health Technol; 2005 Sep; (73):1-4. PubMed ID: 16317826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.
    Genovese MC; Becker JC; Schiff M; Luggen M; Sherrer Y; Kremer J; Birbara C; Box J; Natarajan K; Nuamah I; Li T; Aranda R; Hagerty DT; Dougados M
    N Engl J Med; 2005 Sep; 353(11):1114-23. PubMed ID: 16162882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A nursing guide to infusion therapy with abatacept for the treatment of rheumatoid arthritis.
    Barr C
    J Infus Nurs; 2007; 30(2):96-104; quiz 120. PubMed ID: 17413494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abatacept: A review of a new biologic agent for refractory rheumatoid arthritis for dermatologists.
    Scheinfeld N
    J Dermatolog Treat; 2006; 17(4):229-34. PubMed ID: 16971318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B.
    Kim PS; Ho GY; Prete PE; Furst DE
    Arthritis Care Res (Hoboken); 2012 Aug; 64(8):1265-8. PubMed ID: 22392695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study.
    Weinblatt M; Combe B; Covucci A; Aranda R; Becker JC; Keystone E
    Arthritis Rheum; 2006 Sep; 54(9):2807-16. PubMed ID: 16947384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.
    Genovese MC; Schiff M; Luggen M; Becker JC; Aranda R; Teng J; Li T; Schmidely N; Le Bars M; Dougados M
    Ann Rheum Dis; 2008 Apr; 67(4):547-54. PubMed ID: 17921185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety profile of abatacept in rheumatoid arthritis: a review.
    Khraishi M; Russell A; Olszynski WP
    Clin Ther; 2010 Oct; 32(11):1855-70. PubMed ID: 21095481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Abatacept in the treatment of active rheumatoid arthritis].
    Nielsen H; Hansen A
    Ugeskr Laeger; 2009 Jan; 171(4):214-7. PubMed ID: 19174034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psoriasiform lesions appearing in three patients with rheumatoid arthritis during therapeutic administration of abatacept, a selective inhibitor of T-cell costimulation.
    Konsta M; Rallis E; Karameris A; Stratigos A; Sfikakis PP; Iliopoulos A
    J Eur Acad Dermatol Venereol; 2012 Feb; 26(2):257-8. PubMed ID: 22280512
    [No Abstract]   [Full Text] [Related]  

  • 14. Role of abatacept in the management of rheumatoid arthritis.
    Nogid A; Pham DQ
    Clin Ther; 2006 Nov; 28(11):1764-78. PubMed ID: 17212998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abatacept use after failure of multiple biologic agents in patients with severe rheumatoid arthritis.
    Hazlewood GS; Barnabe C; Barr SG; Martin L
    J Clin Rheumatol; 2012 Dec; 18(8):416-8. PubMed ID: 23188208
    [No Abstract]   [Full Text] [Related]  

  • 16. Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy.
    Genovese MC; Schiff M; Luggen M; Le Bars M; Aranda R; Elegbe A; Dougados M
    J Rheumatol; 2012 Aug; 39(8):1546-54. PubMed ID: 22798265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial.
    Weinblatt M; Schiff M; Goldman A; Kremer J; Luggen M; Li T; Chen D; Becker JC
    Ann Rheum Dis; 2007 Feb; 66(2):228-34. PubMed ID: 16935912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling and simulation of abatacept exposure and interleukin-6 response in support of recommended doses for rheumatoid arthritis.
    Roy A; Mould DR; Wang XF; Tay L; Raymond R; Pfister M
    J Clin Pharmacol; 2007 Nov; 47(11):1408-20. PubMed ID: 17962428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abatacept management during the perioperative period in patients with rheumatoid arthritis: report on eight orthopaedic procedures.
    Nishida K; Nasu Y; Hashizume K; Nakahara R; Ozawa M; Harada R; Machida T; Ozaki T
    Mod Rheumatol; 2014 May; 24(3):544-5. PubMed ID: 24506697
    [No Abstract]   [Full Text] [Related]  

  • 20. Rituximab and abatacept for rheumatoid arthritis.
    BMJ Group
    Drug Ther Bull; 2008 Aug; 46(8):57-61. PubMed ID: 18687584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.